Clinical management of Staphylococcus aureus bacteraemia.
Staphylococcus aureus bacteraemia is one of the most common serious bacterial infections worldwide. In the UK alone, around 12,500 cases each year are reported, with an associated mortality of about 30%, yet the evidence guiding optimum management is poor. To date, fewer than 1500 patients with S au...
Asıl Yazarlar: | Thwaites, G, Edgeworth, J, Gkrania-Klotsas, E, Kirby, A, Tilley, R, Török, M, Walker, S, Wertheim, H, Wilson, P, Llewelyn, M |
---|---|
Materyal Türü: | Journal article |
Dil: | English |
Baskı/Yayın Bilgisi: |
2011
|
Benzer Materyaller
-
Predictors of recurrence, early treatment failure and death from Staphylococcus aureus bacteraemia: observational analyses within the ARREST trial
Yazar:: Szubert, AJ, ve diğerleri
Baskı/Yayın Bilgisi: (2019) -
Clinical and Microbiological Determinants of Outcome in
Staphylococcus aureus Bacteraemia
Yazar:: James Price, ve diğerleri
Baskı/Yayın Bilgisi: (2010-01-01) -
Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial.
Yazar:: Thwaites, G, ve diğerleri
Baskı/Yayın Bilgisi: (2012) -
Clinical sub-phenotypes of Staphylococcus aureus bacteraemia
Yazar:: Swets, MC, ve diğerleri
Baskı/Yayın Bilgisi: (2024) -
Adjunctive rifampicin to reduce early mortality from <it>Staphylococcus aureus</it> bacteraemia (ARREST): study protocol for a randomised controlled trial
Yazar:: Thwaites Guy, ve diğerleri
Baskı/Yayın Bilgisi: (2012-12-01)